RAP-219

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Focal Onset Seizures

Conditions

Focal Onset Seizures

Trial Timeline

Oct 10, 2024 → Sep 26, 2025

NCT ID

NCT06377930

About RAP-219

RAP-219 is a phase 2 stage product being developed by Rapport Therapeutics for Focal Onset Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT06377930. Target conditions include Focal Onset Seizures.

What happened to similar drugs?

4 of 10 similar drugs in Focal Onset Seizures were approved

Approved (4) Terminated (1) Active (6)

✅OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved

✅DapagliflozinAstraZenecaApproved

✅Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved

✅Levetiracetam + Carbamazepine + LamotrigineUCBApproved

🔄Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3

🔄Gadoxetic Acid Disodium (Primovist, BAY86-4873)BayerPhase 3

🔄XEN1101 + PlaceboXenon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07219407	Phase 2	Recruiting	Dec 15, 2025	Feb 3, 2028	Focal Epilepsy
NCT07046494	Phase 2	Recruiting	Jul 25, 2025	Dec 1, 2026	Bipolar 1 Disorder
NCT06377930	Phase 2	Completed	Oct 10, 2024	Sep 26, 2025	Focal Onset Seizures

Competing Products

20 competing products in Focal Onset Seizures

See all competitors

Product	Company	Stage	Hype Score
OnabotulinumtoxinA 145 UNT [Botox]	AbbVie	Approved	35
Dapagliflozin	AstraZeneca	Approved	43
Enfuvirtide + Tenofovir-Emtricitabine	Roche	Phase 2	35
CCX140-B	Amgen	Phase 2	27
PF-06730512	Pfizer	Phase 2	27
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide	Pfizer	Approved	43
VX-147	Vertex Pharmaceuticals	Phase 2	35
VX-147	Vertex Pharmaceuticals	Phase 1	29
IXP	Vertex Pharmaceuticals	Phase 1	29
fresolimumab + fresolimumab + Placebo	Sanofi	Phase 2	35
GC1008 + GC1008 + GC1008 + GC1008	Sanofi	Phase 1	29
frexalimab + brivekimig + rilzabrutinib + placebo	Sanofi	Phase 2	42
Vivaglobin	CSL	Phase 2	35
UCB0942	UCB	Phase 2	27
Levetiracetam + Carbamazepine + Lamotrigine	UCB	Approved	43
Brivaracetam + Brivaracetam	UCB	Phase 2	35
Lacosamide	UCB	Phase 2	27
UCB0942 + UCB0942 + Placebo	UCB	Phase 2	35
Lacosamide	UCB	Pre-clinical	26
ARGX-117	Argenx	Phase 2	36